The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.

Authors :: Al-Ezzi, Esmail M.
Abdeljalil, Osama
Lajkosz, Katherine
Gramolini, Shreya S.
Diaz Mejia, Nely Mercy
Alqaisi, Husam
Peng, Jenny
O'Dwyer, Richard Thomas
Alghamdi, Mohammed
Almuthri, Sulaiman
Kumar, Vikaash
Jiang, Di Maria
Fallah-Rad, Nazanin
Sridhar, Srikala S.
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p179-179, 235p
Publication Year :: 2024

Full Text Access

Tools